This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
A Disintegrin And Metalloproteinase
From Proteopedia
(Difference between revisions)
| Line 15: | Line 15: | ||
== Disease == | == Disease == | ||
| - | ADAM inhibitors are used in anti-cancer therapy. ADAM10 is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. ADAM33 is implicated in asthma. ADAMTS13 cleaves von Willebrand factor involved in blood clotting. | + | ADAM inhibitors are used in anti-cancer therapy. ADAM10 is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. ADAM17 is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>.ADAM33 is implicated in asthma. ADAMTS13 cleaves von Willebrand factor involved in blood clotting. ADAM33 is a therapeutic target for asthma <ref>PMID:383</ref>. |
== 3D Structures of A Disintegrin And Metalloproteinase == | == 3D Structures of A Disintegrin And Metalloproteinase == | ||
Revision as of 10:21, 19 May 2024
| |||||||||||
References
- ↑ Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
- ↑ Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
- ↑ Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
- ↑ Takagi Y, Shikita M. The active form of cytochrome P-450 from bovine adrenocortical mitochondria. J Biol Chem. 1975 Nov 10;250(21):8445-8 PMID:383
